Aava exists because Viralgen is all in on AAV—it’s all we do, all day, every day. As a result, our manufacturing platform, and our Pro10™ cell line, have amassed an impressive 15-years-and-counting record of success for biotech and pharmaceutical partners large and small, from early construct optimization to small feasibility studies to full-on commercial campaigns.

We’ve produced more than 30 AAV serotypes, created upwards of 1,500 AAV batches, and been involved in over four dozen clinical trials.

All of which means you can count on Aava to deliver the perfect combination of speed, scale, predictability, and performance to maximize your opportunities to get life-changing therapies to patients.

Pro10™ Cell Line
Proprietary Pro1O™ is an animal origin-free, suspension-adapted cell line, derived from HEK293 cells. Prolo™ is a unique, high-yield universal system that can produce all serotypes and chimeric forms of rAAV.

Upstream Process
Plasmid-based triple transfection, 50 to 2000L, single-use stirred-tank bioreactors

Downstream Process
Viralgen has the capability of processing 50 to 2000L batches with depth filtration, affinity and ion exchange chromatography and tangential flow filtration, as well as ultracentrifugation for full/empty separation.

Fill & Finish
Fully automated isolator

QC Release & CMC
>80% performed in-house